Serum receptor-binding cancer antigen expressed on SiSo cells (RCAS1) as a diagnostic and prognostic marker for non-small cell lung cancer
Serum receptor-binding cancer antigen expressed on SiSo cells (RCAS1) as a diagnostic and prognostic marker for non-small cell lung cancer
复制标题
DOI：
10.1700/1636.17920
复制
发表时间：
2014-07-01
期刊：
影响因子：
1.9
通讯作者：
Zhang, Xiuwei
中科院分区：
文献类型：
--
作者：
Xu, Chunhua;Yu, Li-ke;Zhang, Xiuwei
背景资料。Siso细胞上表达的受体结合癌症抗原(RCAS1)是一种人类肿瘤相关抗原，可诱导携带RCAS1受体的细胞周期停滞和凋亡。本研究旨在探讨RCAS1水平在非小细胞肺癌诊断和预后判断中的价值。对30例健康志愿者、40例肺部良性疾病患者和97例非小细胞肺癌患者血清进行RCAS1酶联免疫吸附试验，分析血清RCAS1与临床特征的关系。非小细胞肺癌组血清RCAS1水平高于健康志愿者组和肺部良性疾病组(P<；0.001)。以19.8U/ml为临界值，RCAS1诊断非小细胞肺癌的敏感性为87.6%，特异性为82.5%，准确性为86.1%。单因素分析显示，RCAS1值升高的非小细胞肺癌患者的总生存期明显短于其他两组(P=0.042)。经多因素分析，血清RCAS1值是影响预后的独立因素(P=0.003)。检测血清RCAS1水平可作为非小细胞肺癌的诊断和预后指标。
Background. Receptor-binding cancer antigen expressed on SiSo cells (RCAS1) is a human tumor-associated antigen that induces cell-cycle arrest and apoptosis in cells bearing the RCAS1 receptor. The aim of the study was to elucidate the diagnostic and prognostic value of RCAS1 levels in patients with non-small cell lung cancer.Methods. Sera collected from 30 healthy volunteers, 40 patients with benign lung diseases and 97 non-small cell lung cancer cases were subjected to RCAS1 ELISA, and relationships between serum RCAS1 and clinical characteristics were evaluated.Results. Serum RCAS1 levels were higher in the non-small cell lung cancer group than in the healthy volunteers and benign lung disease groups (P < 0.001). With a cutoff level 19.8 U/ml, RCAS1 had a sensitivity of 87.6%, a specificity of 82.5% and an accuracy of 86.1% for non-small cell lung cancer. Univariate analysis revealed that non-small cell lung cancer patients with elevated RCAS1 levels had significantly shorter overall survival (P = 0.042) than the other two groups. By multivariate analysis, serum RCAS1 was identified as an independent prognostic factor (P = 0.003).Conclusions. Assessment of serum RCAS1 levels could be considered as a diagnostic and prognostic marker in non-small cell lung cancer.